Bracco Diagnostics gains FDA approval for updated CardioGen-82 infusion system
Partner News | Published: Wednesday, October 21, 2020
Bracco Diagnostics announced Friday, Oct. 16, that its new CardioGen-82 infusion system for cardiac PET myocardial perfusion imaging (MPI) has received FDA approval.
This new infusion system, which replaces the company’s current offering, was designed to “provide easy access to all system components” while keeping radiation exposure to a minimum. It also includes features focused on decreasing manual record keeping and changing protocol details as needed.
“The new infusion system exemplifies Bracco's significant investment in the cardiac PET imaging modality and is the culmination of thoughtful design and feedback from healthcare providers,” Vittorio Puppo, president and CEO of Bracco Diagnostics, said in a prepared statement.
“Cardiac PET MPI with the CardioGen-82 generator has helped accurately diagnose thousands of patients since 1989,” added Kim McDaniel, senior director of nuclear medicine sales and market support for Bracco Diagnostics. “Bracco was the first company to heavily invest in the modality for the diagnosis of coronary artery disease, and our introduction of the new infusion system is one more example of our commitment to our customers and patients worldwide.”
See original story on CardiovascularBusiness.com.